UBS analyst Matthew Weston upgraded AstraZeneca (AZN:LN) (NASDAQ: AZN) from Sell to Neutral with a price target of GBP113.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE